Evolus, Inc. - Common Stock (NQ:EOLS)

7.220 +0.080 (+1.12%)

Delayed Quote Updated: 10:00 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 17, 2023

Via Benzinga

Evolus Not Affected by Recent Korean Court Ruling

February 10, 2023

From Evolus

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 07, 2023

Via Benzinga

Evolus to Participate in the SVB Securities Global Biopharma Conference

January 31, 2023

From Evolus

Via Business Wire

Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines ↗

January 30, 2023

Via Benzinga

Why Evolus Shares Jumped This Week ↗

January 20, 2023

The company said it expects to turn a profit in the fourth quarter.

Via The Motley Fool

"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance

January 28, 2023

From Evolus

Via Business Wire

Evolus Receives Regulatory Approval for Nuceiva® in Australia

January 23, 2023

From Evolus

Via Business Wire

Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress

January 23, 2023

From Evolus

Via Business Wire

Recap: Evolus Q2 Earnings ↗

August 02, 2022

Evolus (NASDAQ:EOLS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook ↗

January 19, 2023

Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively.

Via Benzinga

Why Evolus Shares Are Trading Higher Today ↗

January 18, 2023

Evolus, Inc. (NASDAQ: EOLS) shares are trading higher after the company issued fourth-quarter and full-year 2022 and announced full-year 2023 revenue guidance.

Via Benzinga

Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 18, 2023

Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+...

Via Benzinga

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration

January 18, 2023

From Evolus

Via Business Wire

Evolus Extends Term of Credit Facility with Pharmakon Advisors

December 08, 2022

From Evolus

Via Business Wire

Evolus Reports Third Quarter 2022 Results and Provides Business Update

November 08, 2022

From Evolus

Via Business Wire

Evolus to Participate in November Conferences

November 02, 2022

From Evolus

Via Business Wire

Evolus to Report Third Quarter 2022 Results and Provide Business Update

October 25, 2022

From Evolus

Via Business Wire

Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

October 04, 2022

From Evolus

Via Business Wire

Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022

September 21, 2022

From Evolus

Via Business Wire

Evolus Announces Inducement Grants for New Chief Financial Officer

September 06, 2022

From Evolus

Via Business Wire

Evolus Appoints Sandra Beaver as Chief Financial Officer

August 30, 2022

From Evolus

Via Business Wire

Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 29, 2022

From Evolus

Via Business Wire

Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

August 24, 2022

From Evolus

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

August 05, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 02, 2022

Via Benzinga

Evolus Reports Second Quarter 2022 Results and Provides Business Update

August 02, 2022

From Evolus

Via Business Wire

Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday ↗

August 03, 2022

Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks.

Via Benzinga

Evolus's Earnings: A Preview ↗

August 01, 2022

Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Evolus will report an...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.